163 related articles for article (PubMed ID: 36257916)
1. Evaluation of pharmacogenomic evidence for drugs related to
Reeves AA; Hopefl R; Deb S
Drug Metab Pers Ther; 2023 Mar; 38(1):65-78. PubMed ID: 36257916
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
3. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.
Yamamoto PA; Conchon Costa AC; Lauretti GR; de Moraes NV
Pharmacogenomics; 2019 Aug; 20(13):971-982. PubMed ID: 31486733
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
Alshabeeb MA; Alyabsi M; Paras B
Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
[TBL] [Abstract][Full Text] [Related]
6. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
[TBL] [Abstract][Full Text] [Related]
7. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Caudle KE; Klein TE; Hoffman JM; Muller DJ; Whirl-Carrillo M; Gong L; McDonagh EM; Sangkuhl K; Thorn CF; Schwab M; Agundez JA; Freimuth RR; Huser V; Lee MT; Iwuchukwu OF; Crews KR; Scott SA; Wadelius M; Swen JJ; Tyndale RF; Stein CM; Roden D; Relling MV; Williams MS; Johnson SG
Curr Drug Metab; 2014 Feb; 15(2):209-17. PubMed ID: 24479687
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
[TBL] [Abstract][Full Text] [Related]
10. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
[TBL] [Abstract][Full Text] [Related]
11. Fetal pharmacogenomics: A promising addition to complex neonatal care.
Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
[TBL] [Abstract][Full Text] [Related]
12. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
[No Abstract] [Full Text] [Related]
13. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.
Shah SN; Gammal RS; Amato MG; Alobaidly M; Reyes DD; Hasan S; Seger DL; Krier JB; Bates DW
Drug Saf; 2021 May; 44(5):601-607. PubMed ID: 33620701
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB.
Alshabeeb MA; Alyabsi M; Aziz MA; Abohelaika S
Front Med (Lausanne); 2022; 9():1001876. PubMed ID: 36388934
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of
Kee PS; Maggo SDS; Kennedy MA; Chin PKL
Front Pharmacol; 2023; 14():1080117. PubMed ID: 36895946
[TBL] [Abstract][Full Text] [Related]
18. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
20. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Hoffman JM; Dunnenberger HM; Kevin Hicks J; Caudle KE; Whirl Carrillo M; Freimuth RR; Williams MS; Klein TE; Peterson JF
J Am Med Inform Assoc; 2016 Jul; 23(4):796-801. PubMed ID: 27026620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
